# EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

> **NCT05176665** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai EpimAb Biotherapeutics Co., Ltd.** · enrollment: 152 (estimated)

## Conditions studied

- Neoplasms
- Neoplasm Metastasis
- Metastatic Gastrointestinal Carcinoid Tumor

## Interventions

- **DRUG:** EMB-01

## Key facts

- **NCT ID:** NCT05176665
- **Lead sponsor:** Shanghai EpimAb Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-21
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2024-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176665, "EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05176665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*